In the United States, almost 74% of adults age 20 and older have overweight or obesity, and of that number almost 42% have obesity. Not only are overweight and obesity complex and serious diseases, but clinicians and researchers are continuing to learn how they can impact health outcomes – from heart and musculoskeletal health to risk for disease, including cancer. New research published in the journal SURGERY shows that obesity is also associated with increased risk of complications following surgery, including infection, blood clots, and kidney complications. “We need to continue to recognize that overweight and obesity can have medical impacts that aren’t limited to heart disease and diabetes and liver failure. They can also make recovery from surgery harder, and these data can inform the conversation happening at a broader public health level addressing obesity.” Robert Meguid, MD, MPH, researcher, professor of cardiothoracic surgery in the ...
The stakes are getting even higher for the fight between Eli Lilly and Novo Nordisk for supremacy in the multibillion-dollar obesity market. Lilly on Friday quietly registered a new phase 3b trial on clinicaltrials.gov. The study, coded SURMOUNT-5, will pit Lilly’s Mounjaro against Novo’s Wegovy in patients with obesity or overweight with weight-related health conditions. The trial aims to enroll 700 participants from 61 sites in the U.S., Canada, South America and several European countries, according to the post. The study is currently expected to officially start next Friday and last for about 78 weeks, with an estimated primary completion date in February 2025. On the study’s primary endpoint, investigators will compare the percentage weight changes between the two drugs by week 72 from baseline. However, it’s not immediately clear whether Lilly is designing SURMOUNT-5 as a superiority study to show Mounjaro is better than Wegovy or just to show ...
Drugs that combat obesity are under consideration for the first time for the World Health Organization’s “essential medicines list,” used to guide government purchasing decisions in low- and middle-income countries, the U.N. agency told Reuters. A panel of advisers to the WHO will review new requests for drugs to be included next month, with an updated essential medicines list due in September. The request to consider obesity drugs was submitted by three doctors and a researcher in the United States. It covers the active ingredient liraglutide in Novo Nordisk’s obesity drug Saxenda, which will come off patent soon, allowing for cheaper generic versions. The panel could reject the request or wait for more evidence. A decision by the WHO to include Saxenda and eventual generics on the list for adults would mark a new approach to global obesity by the health agency. It could also pave the way for a newer, more ...
A team of scientists from the Montreal Neurological Institute and Hospital have reported that people with a high body mass index (BMI) showed reduced visuospatial abilities, cognitive flexibility, and an inability to delay gratification. Other studies that have been conducted also showed that people with a high BMI are more prone to over eating.
Researchers headed by Charlotte M. Wright, MBBS, MSc, MD, professor, Community Child Health, School of Medicine, Dentistry & Nursing, University of Glasgow, Glasgow, Scotland, UK, wrote in Pediatric Obesity,“‘Obesity’ in infancy is not, in fact, an important risk factor for obesity in childhood,”
The AD-36 virus improves blood-sugar and cholesterol levels. Dhurandhar explained, “We think the virus infects fat cells, causing them to divide and grow faster than normal; your body may produce more fat cells, but that means there’s less fat left to travel to your liver and blood.”
Type 1 diabetes is the most common metabolic disorder observed among children. It is a well-known fact that children who have diabetic parents are at higher risk of developing the disease.
HIV infection is associated with a greater risk for abdominal obesity and, perhaps indirectly, a greater risk for elevated LDL cholesterol and hypertriglyceridemia, according to recent findings.
New research published in the Journal of Experimental Medicine highlights the pernicious effect of obesity on the long-term health of blood-making stem cells (hematopoietic stem cells).
Encouraged by evidence of the impact that its diabetes drug semaglutide can have on obesity, with patients shedding an average of 16% of their weight in a mid-stage study, top researchers at Novo Nordisk today unveiled an ambitious late-stage strategy to make their mark in a tough, but potentially blockbuster market.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.